Lilly-backed UK biotech raises $72M to advance its antibody approach — Solasta Ventures
Solasta Ventures
Home Approach Portfolio
News Team Hatchery Contact
HomeApproachPortfolio
Solasta Ventures
NewsTeamHatcheryContact
Lilly-backed UK biotech raises $72M to advance its antibody approach
Nia JulianMarch 17, 2025
Facebook0 Twitter Pinterest0 0 Likes
Next

AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal

Nia JulianFebruary 13, 2025

© 2020 Solasta Ventures. All Rights Reserved.